TY - JOUR
T1 - Survival in young patients with intermediate/high-risk myelofibrosis
T2 - Estimates derived from databases for non transplant patients
AU - Siragusa, Sergio
AU - Passamonti, Francesco
AU - Cervantes, Francisco
AU - Tefferi, Ayalew
PY - 2009/3
Y1 - 2009/3
N2 - Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontrans-plant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF.
AB - Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontrans-plant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced-intensity conditioning allo-SCT. These observations underscore the need for controlled studies to accurately assess the value of allo-SCT in PMF.
UR - http://www.scopus.com/inward/record.url?scp=62949209453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62949209453&partnerID=8YFLogxK
U2 - 10.1002/ajh.21342
DO - 10.1002/ajh.21342
M3 - Article
C2 - 19123461
AN - SCOPUS:62949209453
SN - 0361-8609
VL - 84
SP - 140
EP - 143
JO - American journal of hematology
JF - American journal of hematology
IS - 3
ER -